INS and Hyperglycemia: Three of the studies reduced the total insulin daily dose by 25% in the experimental groups, and the result was no difference in hyperglycemia compared to regular dosing (24), no episodes of DKA or NKHS (no comparator) (28), and no difference in A1c or average blood glucose compared to regular dosing (29).